

Figure S1. Cell-free DNA concentration in plasma stratified by ctDNA status. Boxes extend from the 25-75th percentile. ctDNA, circulating tumor DNA; ns, not significant.




Figure S2. Association between changes in mutation burden and individual clinical responses during pembrolizumab treatments. PD, progressive disease; PR, partial response; SD, stable disease; SNV, small nucleotide variants.

